Eptifibatide: Difference between revisions

Jump to navigation Jump to search
ShiSheng (talk | contribs)
No edit summary
ShiSheng (talk | contribs)
No edit summary
Line 36: Line 36:


{{Reflist|2}}  
{{Reflist|2}}  
{{Antithrombotics}}


[[Category:Antiplatelet drugs]]
[[Category:Antiplatelet drugs]]

Revision as of 21:40, 5 February 2014


Eptifibatide
INTEGRILIN® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Eptifibatide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Eptifibatide, click here

Synonyms / Brand Names: INTEGRILIN®

Overview

Category

Cardiovascular Drugs:Antiplatelet drugs

FDA Package Insert

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

Template:WikiDoc Sources